The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AGEN | -9.8% | -94.76% | -44.56% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +370% |
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $25.69M | 9.3% |
| Gross Profit | $22.28M | 11.2% |
| Gross Margin | 86.72% | 1.5% |
| Market Cap | $125.29M | -64.4% |
| Market Cap / Employee | $0.40M | 0.0% |
| Employees | 316 | -18.8% |
| Net Income | -$30.01M | 45.2% |
| EBITDA | -$13.61M | 49.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.53M | -89.8% |
| Accounts Receivable | $0.71M | -1.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $285.07M | 18.8% |
| Short Term Debt | $117.69M | -31.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -69.29% | -3.2% |
| Return On Invested Capital | 67.41% | -1050.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.22M | 47.7% |
| Operating Free Cash Flow | -$20.22M | 47.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.41 | -0.20 | -0.11 | -0.36 | -79.66% |
| Price to Sales | 0.74 | 0.60 | 0.37 | 1.26 | -42.83% |
| Price to Tangible Book Value | -0.37 | -0.19 | -0.10 | -0.33 | -78.46% |
| Enterprise Value to EBITDA | -17.14 | -19.11 | -44.99 | -39.67 | 54.01% |
| Total Debt | $420.60M | $431.35M | $416.94M | $402.76M | -2.15% |
AGEN earnings call for the period ending December 31, 2024.
AGEN earnings call for the period ending September 30, 2024.
AGEN earnings call for the period ending June 30, 2024.
AGEN earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
